Traditional urological concerns, such as bladder instability, bladder cancer, prostate cancer and incontinence, were focused upon. In addition, significant attention was paid to erectile dysfunction, with varied developments in the field. Capsaicin was presented as having a role to play in the reduction of bladder instability, while a new formulation of oxybutinin was shown to improve female urge incontinence. The combination of topical estrogen and an oral agonist, phenylpropanolamine, also gave significant improvement in menopausal urinary urgency and incontinence. Tetrahydropyranyladriamycin (THPA) will possibly be effective for adequate prophylaxis against the recurrence of early bladder cancer. COX-2 receptor modulation has a role in the treatment of bladder cancer, whilst the endothelin receptor antagonist ABT-627 (Abbott International Ltd) may prove effective in the treatment of prostate cancer. Melanotan II (PNU-83757; Pharmacia and Upjohn Inc) and IC-351 (Icos Corp) are new compounds for the treatment of erectile dysfunction (ED), and more light is shed on a role for apomorphine for the same indication.
Download full-text PDF |
Source |
---|
World J Urol
January 2025
Department of Urology, Peking University People's Hospital, Beijing, 100044, China.
Purpose: This study aims to elucidate the role of pituitary adenylate cyclase-activating polypeptide (PACAP) in Hunner-type Interstitial Cystitis (HIC) and evaluate its potential as a therapeutic target.
Methods: Bladder tissue samples were obtained from HIC patients and normal bladder tissue from bladder cancer patients. PACAP expression was assessed through immunohistochemistry.
Sci Rep
January 2025
Institute for System Dynamics, University of Stuttgart, Waldburgstr. 19, 70563, Stuttgart, Germany.
Including sensor information in medical interventions aims to support surgeons to decide on subsequent action steps by characterizing tissue intraoperatively. With bladder cancer, an important issue is tumor recurrence because of failure to remove the entire tumor. Impedance measurements can help to classify bladder tissue and give the surgeons an indication on how much tissue to remove.
View Article and Find Full Text PDFInt J Urol
January 2025
Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Introduction: Bowel regimens (BR) before radical cystectomy (RC) are currently not recommended by Enhanced Recovery After Surgery (ERAS) protocols, as prior studies have shown BRs lead to worsened outcomes. However, many of those studies have used historic literature before recent surgical advancements such as minimally invasive RC and have not investigated the impact BRs have by type of urinary diversion. Our goal is to determine the outcomes of preoperative BR in patients undergoing RC based on diversion type using a modern patient cohort.
View Article and Find Full Text PDFCancer Lett
January 2025
Department of Radiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China, 210029; The Affiliated Suqian First People's Hospital of Nanjing Medical University, Suqian, Jiangsu Province, China. Electronic address:
Preoperative detection of muscle-invasive bladder cancer (MIBC) remains a great challenge in practice. We aimed to develop and validate a deep Vesical Imaging Network (ViNet) model for the detection of MIBC using high-resolution Tweighted MR imaging (hrTWI) in a multicenter cohort. ViNet was designed using a modified 3D ResNet, in which, the encoder layers were pretrained using a self-supervised foundation model on over 40,000 cross-modal imaging datasets for transfer learning, and the classification modules were weakly supervised by an experiential knowledge-domain mask indicated by a nnUNet segmentation model.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
January 2025
Department of Urology, University of Tsukuba, Ibaraki, Japan. Electronic address:
Purpose: Bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) trial, which was a multicenter, open-label, single-arm phase II study, showed a promisingly high interim clinical complete response (cCR) rate of 84.4% (38/45). In the present study, we aimed to identify potential tissue biomarkers for achieving cCR via BPT-ART.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!